News Sentiment

CGEN sentiment intelligence

Compugen news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors Options RSS feed
Weighted score 52 Balanced news tone 64 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 2.35 Week of 31 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Earnings

76/100 classification confidence.

Company focus 55

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend active

+3.1% over one week, +3.1% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Compugen Stock: Better Runway Ahead Of MAIA (NASDAQ:CGEN)

Market Reaction

Balanced read

59/100 confidence

News tone and price action are not far from neutral.

Primary event Earnings 76/100 classification
One-week reaction 3.1% Price confirming higher
Trend fit Trend active 3.1% over four weeks
Fair value 32.2% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 12
Neutral 44
Negative 8

Relevance

Why the article matched

Direct first
Direct company coverage 55
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 13
Market source 10
TradingKey 7
TradingView 4
simplywall.st 4
Moomoo 3
PR Newswire 3
Seeking Alpha 2

Event Lens

What the news is about

Classified themes
Earnings 31
Market update 27
Analyst action 3
Balance sheet 2
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 64
Yahoo! Finance Canada Direct company coverage

Compugen Ltd. (CGEN) Stock Price, News, Quote & History

This article provides a detailed financial overview of Compugen Ltd. (CGEN), a clinical-stage therapeutic discovery and development company. It covers the company's stock price, historical data, key financial metrics, recent news, performance against benchmarks, and analyst ratin

Tone
Neutral 50/100
Event
Analyst action
Published
05 Aug 2026 01:11
Source
Yahoo! Finance Canada
Investing.com Direct company coverage

Compugen stock maintained at Buy by H.C. Wainwright on trial data

H.C. Wainwright reiterated a Buy rating and a $4.00 price target for Compugen (NASDAQ:CGEN) after the company revised assumptions for its MAIA-ovarian study. Compugen adjusted its estimated median progression-free survival for the placebo arm to four months, down from 5.5 months,

Tone
Positive 76/100
Event
Analyst action
Published
04 Aug 2026 11:14
Source
Investing.com
Simply Wall Street Direct company coverage

Compugen (CGEN) Stock Holds Steady As Cash Runway Extends To 2029

Compugen's stock remained stable after its Q2 2026 earnings report, which showed increased revenue and a slightly smaller net loss year-over-year. The company's cash position of approximately US$125.3 million is expected to fund operations into 2029, supporting its clinical and p

Tone
Neutral 50/100
Event
Earnings
Published
04 Aug 2026 06:10
Source
Simply Wall Street
Moomoo Direct company coverage

Press Release: Compugen Reports Second Quarter 2026 Results

This press release from Compugen reports their financial and operational results for the second quarter of 2026. It will likely detail key achievements, financial performance metrics, and potentially updates on their drug development pipeline.

Tone
Neutral 50/100
Event
Earnings
Published
03 Aug 2026 21:41
Source
Moomoo
AlphaStreet Direct company coverage

Compugen Releases Q2 2026 Financial Results

Compugen Ltd. reported its Q2 2026 financial results, showcasing a narrower loss of $0.07 per share, beating analyst expectations, and a significant revenue increase of 107.0% to $2.6M. The clinical-stage therapeutic discovery company recorded a net loss of $7.0M as it continues

Tone
Positive 70/100
Event
Earnings
Published
03 Aug 2026 19:10
Source
AlphaStreet
Pluang Direct company coverage

Compugen's ovarian cancer trial on track with key data due Q1 2027; strong financials support pipeline through 2029

Compugen Ltd. announced significant progress in its MAIA-ovarian trial for platinum-sensitive ovarian cancer, with key progression-free survival data expected in Q1 2027. The company also highlighted advancements in collaborations with AstraZeneca and Gilead and reported a strong

Tone
Positive 71/100
Event
Market update
Published
03 Aug 2026 13:12
Source
Pluang
Moomoo Direct company coverage

Compugen: Cash Runway Expected to Fund Ops Into 2029 >CGEN.TV

Compugen announced that its current cash reserves are projected to fund operations well into 2029. This extended cash runway provides the company with significant financial stability and flexibility for its ongoing research and development efforts.

Tone
Positive 70/100
Event
Balance sheet
Published
03 Aug 2026 12:10
Source
Moomoo
Associated Press Direct company coverage

Compugen: Q2 Earnings Snapshot

Tone
Neutral 50/100
Event
Earnings
Published
03 Aug 2026 11:03
Source
Associated Press
Market source Direct company coverage

Compugen Reports Second Quarter 2026 Results

Compugen Ltd. announced its second-quarter 2026 financial results, highlighting the progress of its MAIA-ovarian trial for COM701, with median progression-free survival data expected by Q1 2027. The company also reported advancements in its partnered programs with AstraZeneca and

Tone
Neutral 50/100
Event
Earnings
Published
03 Aug 2026 11:10
Source
Market source
www.marketscreener.com Direct company coverage

Compugen Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Compugen Ltd. announced its financial results for the second quarter and six months ended June 30, 2026. For Q2 2026, the company reported sales of USD 2.6 million, an increase from USD 1.26 million in the prior year, with a net loss of USD 7.01 million. For the six-month period,

Tone
Positive 57/100
Event
Earnings
Published
03 Aug 2026 10:36
Source
www.marketscreener.com
TradingView Direct company coverage

Compugen Ltd expected to post a loss of 8 cents a share - Earnings Preview

Compugen Ltd is expected to report a loss of 8 cents per share, according to a recent earnings preview. This information was sourced from Refinitiv and highlighted by TradingView News. The full article is available through a paid subscription service.

Tone
Negative 29/100
Event
Earnings
Published
31 Jul 2026 12:40
Source
TradingView
TradingView Direct company coverage

CGEN Q2'26 Earnings: EPS estimate is (0.08) USD

Compugen Ltd. (CGEN) is scheduled to release its Q2'26 earnings before the market opens on August 03, with an anticipated revenue of 1.28 million USD and an EPS estimate of (0.08) USD. The article provides a detailed table of past and estimated revenue and EPS figures, highlighti

Tone
Negative 42/100
Event
Earnings
Published
31 Jul 2026 10:40
Source
TradingView
Stock Titan Direct company coverage

Compugen (CGEN) grants director options and RSUs with long vesting

Compugen director Eran Perry received two equity awards on July 29, 2026: 10,000 share options at an exercise price of $2.26 and 7,500 restricted stock units (RSUs). Both awards have a long vesting schedule, with 25% vesting on October 1, 2027, and the remainder vesting in 12 equ

Tone
Neutral 50/100
Event
Market update
Published
31 Jul 2026 09:41
Source
Stock Titan
Stock Titan Direct company coverage

Compugen (CGEN) awards 100,000 share options to director Anat Cohen-Dayag

Compugen Ltd. (CGEN) has awarded 100,000 share options to director Anat Cohen-Dayag, allowing her to purchase Ordinary Shares at an exercise price of $2.2600 per share. These options, which expire on July 29, 2036, will vest 25% on September 30, 2027, with the remainder vesting i

Tone
Neutral 50/100
Event
Market update
Published
30 Jul 2026 21:09
Source
Stock Titan
Stock Titan Direct company coverage

Compugen (CGEN) awards CEO Ophir Eran 200,000 share options

Compugen Ltd. (CGEN) CEO Ophir Eran was granted 200,000 share options for ordinary shares on July 29, 2026. These options have an exercise price of $2.2600 and are set to expire on July 29, 2036. The options will vest 25% on September 30, 2027, with the remaining 75% vesting in 1

Tone
Neutral 50/100
Event
Market update
Published
30 Jul 2026 20:40
Source
Stock Titan
Stock Titan Direct company coverage

Compugen (CGEN) grants CFO 26,000 options and 19,500 RSUs

Compugen Ltd. (CGEN) has granted its Chief Financial Officer, David Silberman, 19,500 restricted stock units (RSUs) and 26,000 share options, with an exercise price of $2.26 and an expiration date of July 29, 2036. Both awards will vest 25% on September 30, 2027, with the remaind

Tone
Neutral 50/100
Event
Market update
Published
30 Jul 2026 20:40
Source
Stock Titan
Investing.com Nigeria Direct company coverage

Form 4 COMPUGEN LTD For: 30 July By Investing.com

This article reports on a Form 4 filing for COMPUGEN LTD on July 30, 2026. Form 4 filings are legally required documents filed with the SEC whenever there is a material change in the holdings of company insiders. The article provides a brief overview of the filing, referencing Re

Tone
Neutral 50/100
Event
Market update
Published
30 Jul 2026 20:40
Source
Investing.com Nigeria
Stock Titan Direct company coverage

Compugen (CGEN) awards options and RSUs to board director

Compugen Ltd. (CGEN) director Mathias Hukkelhoven was granted equity awards on July 29, 2026. The awards include options for 10,000 Ordinary Shares with a $2.26 exercise price and an RSU award for 7,500 shares. Both awards are subject to vesting schedules tied to his continued se

Tone
Neutral 50/100
Event
Market update
Published
30 Jul 2026 20:39
Source
Stock Titan
Stock Titan Direct company coverage

COMPUGEN LTD (CGEN) grants 24,000 share options and 18,000 RSUs to SVP

COMPUGEN LTD (CGEN) has granted SVP of Business Development, Zurit Levine, 18,000 restricted stock units (RSUs) and 24,000 share options with an exercise price of $2.26 per share. Both awards have an initial vesting of 25% on September 30, 2027, with the remainder vesting in 12 e

Tone
Neutral 50/100
Event
Market update
Published
30 Jul 2026 20:39
Source
Stock Titan